Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetyl Hexapeptide-8 in Blepharospasm
NCT00942851Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jul 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetyl hexapeptide-8 in benign essential blepharospasm (BEB) (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline. Started Jul 2009; status: completed.
02
Drugs
acetyl hexapeptide-8
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT00942851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942851.